On October 22, 2026 Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, reported its sales for the year-to-date and third quarter of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

YTD
2026 YTD
2025 %
change Q3
2026 Q3
2025 %
change
€m €m Actual CER €m €m Actual CER
Oncology 2,196.9 1,912.0 14.9% 16.3% 745.4 624.0 19.4% 17.7%
Rare Disease 498.2 255.4 95.0% 100.1% 193.5 102.0 89.6% 88.6%
Neuroscience 669.1 567.3 17.9% 18.8% 235.1 188.9 24.4% 23.1%
Total Sales 3,364.2 2,734.8 23.0% 24.6% 1,173.9 915.0 28.3% 26.7%
"Our outstanding performance in the first nine months of 2026 is driven by the strength of our core portfolio and continued growth of Somatuline. This momentum, combined with disciplined execution, supports our further upgraded sales and margin guidance for the year," said David Loew, Chief Executive Officer, Ipsen. "Looking ahead, we are excited by the significant opportunities emerging from our pipeline. We have the potential to address substantial unmet needs and expand our reach to new patient populations through Dysport in episodic and chronic migraine and, through Iqirvo with a potential label update in primary biliary cholangitis. We also look forward to the Phase III readout of navtemadlin in myelofibrosis next year. Together with potravitug in post-transplant nephropathy, these differentiated late-stage assets underscore our ambition to bring forward new medicines with blockbuster potential and make a meaningful difference for patients."

Full-year 2026 guidance
Based on the strong year-to-date performance, Ipsen further upgrades its financial guidance for 2026:

Total sales growth around 23.0%, at CER. Based on the current average level of exchange rates in October, an adverse effect from currencies of around 0.5% on total sales is expected
Core operating margin around 39.0% of total sales
Full-year guidance on total sales and core operating margin assumes strong double-digit sales growth of the core portfolio and the growth of Somatuline sales despite the assumed entry of generic lanreotide in the fourth quarter.

External innovation
During the third quarter, Ipsen completed the acquisitions of Memo Therapeutics and Kartos Therapeutics, adding potravitug, a late-stage anti-BK polyomavirus monoclonal antibody, and navtemadlin, a Phase III MDM2 inhibitor for myelofibrosis. These transactions further strengthen Ipsen’s Rare Disease and Oncology pipelines and support the Group’s strategy of building long-term growth through differentiated late-stage assets.

Pipeline update
Ipsen strengthened its late-stage pipeline, advancing key programs and expanding into new disease areas:

In Oncology, the acquisition of navtemadlin, alongside IPN60340, expanded Ipsen’s late-stage presence in hematology across myelofibrosis and acute myeloid leukemia
In Rare Disease, elafibranor continues Phase III development in primary sclerosing cholangitis and regulatory filings for Iqirvo in primary biliary cholangitis are underway, while the recently acquired potravitug adds a Phase II/III program in post-transplant nephropathy
In Neuroscience, regulatory submissions are underway for Dysport as a first botulinum toxin to achieve positive topline Phase III results in chronic and episodic migraine, while corabotase first-in-class recombinant neuroinhibitor (RNITM) progresses through Phase II and Phase III development across therapeutic and aesthetic indications
Galderma arbitration
In October 2026, Galderma initiated two further arbitration proceedings before the International Court of Arbitration of the International Chamber of Commerce (ICC) and the American Arbitration Association (AAA) concerning Ipsen’s new proprietary recombinant neuroinhibitor corabotase. Ipsen disagrees with Galderma’s position regarding the distribution agreements entered into between the Parties since 2007 and intends to vigorously defend its position in both proceedings. In separate proceedings, an ICC Arbitral Tribunal issued a final ruling in January 2026 in favor of Ipsen, dismissing Galderma’s claim related to Ipsen’s alleged wrongful termination of the R&D agreement entered into in 2014; as a result, Ipsen regained full rights to its clinical stage programs in the aesthetic field. Ipsen cannot at this stage reasonably predict the outcome of the proceedings or any potential financial impact.

Conference call
A conference call and webcast for investors and analysts will begin today at 1pm CEST. Participants can access the webcast here. Analysts can join the call and ask questions by registering here.

Calendar
Ipsen intends to publish its full-year results and fourth-quarter sales on 11 February 2027.

Notes
All financial figures are in € millions (€m). The performance shown in this announcement covers the nine-month period to 30 September 2026 (YTD 2026) and the three-month period to 30 September 2026 (Q3 2026), compared to the nine-month period to 30 September 2025 (YTD 2025) and the three-month period to 30 September 2025 (Q3 2025), respectively, unless stated otherwise. Commentary is based on the performance in YTD 2026, unless stated otherwise.

(Press release, Ipsen, OCT 22, 2026, View Source [SID1234673671])